Pardoprunox

Uses your system voice; voice and rate in settings.

Snapshot

≈ 2 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Pardoprunox (INN; code name SLV-308) is an antiparkinsonian drug developed by Solvay for the treatment of Parkinson's disease that reached phase III clinical trials before being discontinued. It was also being investigated for the treatment of [[major depression|depression] and anxiety but these indications appear to have been abandoned as well. Pardoprunox acts as a D 2 (pK i = 8.1) and D 3 receptor (pK i = 8.6) partial agonist (IA = 50% and 67%, respectively) and 5-HT 1A receptor (pK i = 8.5) full agonist (IA = 100%). It also binds to D 4 (pK i = 7.8), α 1 -adrenergic (pK i = 7.8), α 2 -adrenergic (pK i = 7.4), and 5-HT 7 receptors (pK i = 7.2) with lower affinity. Relative to other dopaminergic antiparkinsonian agents, pardoprunox is thought to have significantly less of a propensity for inducing certain side effects like dyskinesia and psychosis.

Pardoprunox (INN; code name SLV-308) is an antiparkinsonian drug developed by Solvay for the treatment of Parkinson's disease that reached phase III clinical trials before being discontinued. It was also being investigated for the treatment of depression and anxiety but these indications appear to have been abandoned as well. Pardoprunox acts as a D 2 (pK i = 8.1) and D 3 receptor (pK i = 8.6) partial agonist (IA = 50% and 67%, respectively) and 5-HT 1A receptor (pK i = 8.5) full agonist (IA = 100%). It also binds to D 4 (pK i = 7.8), α 1 -adrenergic (pK i = 7.8), α 2 -adrenergic (pK i = 7.4), and 5-HT 7 receptors (pK i = 7.2) with lower affinity. Relative to other dopaminergic antiparkinsonian agents, pardoprunox is thought to have significantly less of a propensity for inducing certain side effects like dyskinesia and psychosis.

See also

List of investigational Parkinson's disease drugs Aripiprazole Bifeprunox

References

Further reading

Text derived from https://en.wikipedia.org/w/index.php?oldid=1338600496 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

Extracted from the cited revision's reference blocks; absent citations are not invented.